FDA approves new drug reflecting cutting-edge, ’tissue-agnostic’ effort to beat cancer

Vitrakvi, a new tissue-agnostic cancer drug — or one that targets tumors caused by TRK fusion — has been approved by the FDA, reports John Bacon for USA Today.

For many patients, this is the only possible treatment for their disease. “There had been no treatment for cancers that frequently express this mutation,” the FDA announced.

Bayer, the company behind the drug has promised to make it affordable to all who need it.

This entry was posted in Health Issues. Bookmark the permalink.
  • One World Observatory

    Learn more about the One World Observatory complimentary ticket program.

  • Categories

  • From the Newsletter

  • Upcoming Events

    1. COVID-19 testing sites in the NYC area

      October 13 @ 8:00 am - December 31 @ 5:00 pm
    2. Application period open for the LeRoy W. Homer, Jr. Foundation Scholarship

      November 1, 2020 @ 8:00 am - January 31, 2021 @ 5:00 pm
    3. Buy a beer on Mondays and support the Terry Farrell Foundation – Fort Collins, CO

      November 7 @ 11:00 am - December 31 @ 8:00 pm
    4. NYPD Officer Chris Bramwell needs a kidney urgently

      November 10 @ 8:00 am - December 31 @ 5:00 pm
    5. Warren Fire Department fundraiser for their 9/11 ceremony next year

      November 17, 2020 @ 8:00 am - January 31, 2021 @ 5:00 pm